跳至主要内容
临床试验/RPCEC00000106
RPCEC00000106已完成2 期

Human Recombinant Epidermal Growth Factor in patients with venous ulcers.

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.0 个研究点目标入组 50 人开始时间: 2011年5月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
18 years 至 /A (No limit)(—)
性别
All

入选标准

  • 1.Informed consent of patient. 2.Age major than 18 years old. 3.Diagnosis of an only venous ulcer in lower limbs, not infected, up to 1 cm2 and minor than 10 cm2.

排除标准

  • 1.Diabetes mellitus, Sickle Cell anemia. 2.Cancer (except the basal cell carcinoma and the cervix cancer in situ after surgery and complete cured). 3.Metabolic disease (liver disease, renal disease, pancreatic diseases, colagenosis) Mild o serious anemia (Hb = 11 g/L for women y 12 g/L for men). 4.Severely disabled (caquexia, critical patients, life-threatening diseases). 5.Uncontrolled Hypertension due to clinical examination. 6.Peripheral arterial chronic diseases referred by patient and confirm bay clinical examination. 7.Patients treated with steroids in the last 3 months. 8.Patients treated with EGF in the last 30 days. 9.Serious psychiatric disorder and other disease that limit informed consent. 10.Pregnancy or nursery.

研究者

发起方
Center for Genetic Engineering and Biotechnology (CIGB), in Havana.

相似试验